TGM2 Protein
Overview
Transglutaminase 2 (TGM2), also known as tissue transglutaminase (tTG), is a multifunctional calcium-dependent enzyme belonging to the transglutaminase family. Encoded by the TGM2 gene located on chromosome 20q11.2, this ~77 kDa protein is ubiquitously expressed across human tissues with particularly high levels in the brain, smooth muscle, and immune cells. TGM2 exists in both intracellular and extracellular compartments, with its subcellular localization including the cytoplasm, nucleus, mitochondria, and plasma membrane. The protein exhibits remarkable functional versatility, operating as both an enzyme and a non-enzymatic scaffolding protein depending on cellular context and calcium availability[@pmid35913916].
Function and Biology
TGM2 catalyzes two primary enzymatic reactions: transamidation (crosslinking) and deamidation. In its classical transamidation function, TGM2 catalyzes the formation of isopeptide bonds between glutamine residues (acyl donor) and lysine residues (acyl acceptor) on target proteins, or between glutamine and primary amines. This crosslinking stabilizes protein networks and modifies protein properties. Through deamidation, TGM2 converts glutamine residues to glutamic acid, altering protein charge and function without forming covalent crosslinks.
...TGM2 Protein
Overview
Transglutaminase 2 (TGM2), also known as tissue transglutaminase (tTG), is a multifunctional calcium-dependent enzyme belonging to the transglutaminase family. Encoded by the TGM2 gene located on chromosome 20q11.2, this ~77 kDa protein is ubiquitously expressed across human tissues with particularly high levels in the brain, smooth muscle, and immune cells. TGM2 exists in both intracellular and extracellular compartments, with its subcellular localization including the cytoplasm, nucleus, mitochondria, and plasma membrane. The protein exhibits remarkable functional versatility, operating as both an enzyme and a non-enzymatic scaffolding protein depending on cellular context and calcium availability[@pmid35913916].
Function and Biology
TGM2 catalyzes two primary enzymatic reactions: transamidation (crosslinking) and deamidation. In its classical transamidation function, TGM2 catalyzes the formation of isopeptide bonds between glutamine residues (acyl donor) and lysine residues (acyl acceptor) on target proteins, or between glutamine and primary amines. This crosslinking stabilizes protein networks and modifies protein properties. Through deamidation, TGM2 converts glutamine residues to glutamic acid, altering protein charge and function without forming covalent crosslinks.
The enzyme requires calcium ions (Ca²⁺) for full enzymatic activity, with its open conformation in the presence of high intracellular calcium enabling access to the catalytic triad (Cys277, His335, Asp358). Under basal conditions with low intracellular calcium, TGM2 adopts a compact, inactive conformation. Notably, TGM2 also functions as a GTPase-activating protein (GAP) and protein disulfide isomerase, activities independent of its transglutaminase function. These diverse roles reflect TGM2's structural complexity and its integration into multiple cellular signaling networks.
Role in Neurodegeneration
Accumulating evidence implicates TGM2 in multiple neurodegenerative diseases through protein aggregation, oxidative stress amplification, and neuroinflammation. In Alzheimer's disease, TGM2 crosslinks amyloid-beta (Aβ) peptides and tau protein, promoting the formation of pathological protein aggregates resistant to proteolytic degradation. These crosslinked species show increased neurotoxicity and resistance to clearance mechanisms. The enzyme's activity correlates with amyloid plaque density and tau tangle burden in post-mortem Alzheimer's brain tissue.
In Parkinson's disease, TGM2 catalyzes the crosslinking of α-synuclein monomers into insoluble oligomers and fibrils. TGM2-mediated crosslinking of α-synuclein generates pathological species that seed further aggregation and propagate cell-to-cell, potentially driving disease progression. Enhanced TGM2 expression occurs in dopaminergic neurons of Parkinson's patients, particularly in regions containing Lewy bodies.
In Huntington's disease, TGM2 crosslinks mutant huntingtin (mHTT) protein, facilitating the formation of inclusion bodies. Similarly, in amyotrophic lateral sclerosis (ALS), TGM2 promotes aggregation of superoxide dismutase 1 (SOD1) and the RNA-binding protein TDP-43, key pathological hallmarks of disease.
Molecular Mechanisms
TGM2-mediated neurodegeneration operates through several interconnected mechanisms. Protein crosslinking creates highly stable, proteasome-resistant aggregates that sequester cellular resources and impair proteostasis. These pathological crosslinks can propagate in prion-like fashion, transferring aggregation properties between cells. TGM2 activity generates reactive oxygen species (ROS) through its function as a protein disulfide isomerase, exacerbating oxidative stress and mitochondrial dysfunction. Additionally, extracellular TGM2 facilitates cross-talk between neuroinflammatory pathways, promoting microglial activation and astrocyte-mediated neuroinflammation through transglutaminase-dependent deposition in extracellular matrix.
Calcium dysregulation, a hallmark of neurodegeneration, simultaneously activates TGM2 and promotes conditions favoring protein aggregation, creating a pathological feedback loop. Excitotoxicity and ischemic insults elevate intracellular calcium, activating TGM2 and worsening protein aggregation burden.
Clinical and Research Significance
TGM2 represents an attractive therapeutic target for neurodegenerative disease intervention. Transglutaminase inhibitors, including cystamine and its derivatives, show neuroprotective effects in preclinical models by reducing pathological protein crosslinking. Research into selective TGM2 inhibitors aims to block the deleterious enzymatic functions while preserving non-enzymatic scaffolding roles critical for normal physiology. Modulation of TGM2 expression and activity may represent disease-modifying strategies complementary to existing approaches